June 2016. Volume 12. Number 2

Palivizumab seems to have no long-term effect on lung function

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Prais D, Kaplan E, Klinger G, Mussaffi H, Mei-Zahav M, Bar-Yishay E, Stafler P, Steuer G, Sirota L, Blau H. Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely. Chest. 2016 ;149:801-8.
Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 17/05/2016
Acceptance date: 20/05/2016
Publication date: 25/05/2016

Abstract

Authors’ conclusions: palivizumab prophylaxis was associated with reduced wheezing episodes and hospitalizations during the first two years of life in children born extremely prematurely. However, it did not affect pulmonary outcome at school age.

Reviewers’ commentary: the results of this study, because of the design (observational with historical control), small and unrepresentative sample, discordant short- and long-term results, do not support long-term effect of palivizumab on respiratory symptoms or lung function. Estimates of short-term effect are very imprecise.

.

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. El palivizumab no parece tener efecto a largo plazo sobre la función pulmonar. Evid Pediatr. 2016;12:30.

AVC | Critically appraised articles

Prais D, Kaplan E, Klinger G, Mussaffi H, Mei-Zahav M, Bar-Yishay E, Stafler P, Steuer G, Sirota L, Blau H. Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely. Chest. 2016 ;149:801-8.
Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 17/05/2016
Acceptance date: 20/05/2016
Publication date: 25/05/2016

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. El palivizumab no parece tener efecto a largo plazo sobre la función pulmonar. Evid Pediatr. 2016;12:30.

References

  1. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. 1998;102: 531-37.
  2. González de Dios J, Ochoa Sangrador C. La inmunización con palivizumab frente al virus respiratorio sincitial solo es coste-efectiva en prematuros con displasia broncopulmonar y en los meses de alto riesgo de la infección. Evid Pediatr. 2010;6:81.
  3. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab long-term respiratory outcomes Study Group. Palivizumab prophylaxis respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151:34-42.
25/05/2016

Linked Comment